Lucira Health Announces Closing of its Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Lucira Health recently closed its upsized IPO, selling 10,350,000 shares at $17.00 per share, generating gross proceeds of $175.95 million. The underwriters exercised their option for an additional 1,350,000 shares. Lucira's common stock commenced trading on Nasdaq under the symbol 'LHDX' on February 5, 2021. The offering was managed by BofA Securities and William Blair, with registration statements effective as of February 4, 2021. Lucira Health specializes in innovative infectious disease testing kits that deliver accurate results in a consumer-friendly format.
- Successfully raised $175.95 million through the IPO, enhancing liquidity for future developments.
- Expanded public profile with shares listed on Nasdaq under 'LHDX'.
- Strong demand indicated by the underwriters' full exercise of their option for additional shares.
- None.
Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced the closing of its upsized initial public offering of 10,350,000 shares of its common stock, which includes 1,350,000 shares sold pursuant to the full exercise by the underwriters of their option to purchase additional shares, at a public offering price of
Lucira’s common stock began trading on the Nasdaq Global Select Market on February 5, 2021 under the ticker symbol “LHDX.”
BofA Securities and William Blair acted as lead bookrunning managers and LifeSci Capital acted as co-manager for the offering.
The offering was made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained from: BofA Securities, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, or by telephone at (800) 294-1322, or by email at dg.prospectus_requests@bofa.com, or William Blair, Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, or by telephone at (800) 621-0687 or email at prospectus@williamblair.com.
Registration statements relating to these securities have been filed with the Securities and Exchange Commission and became effective on February 4, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Lucira Health
Lucira Health is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. Lucira has developed a testing platform that produces centralized-laboratory-accurate molecular testing in a single-use and consumer-friendly test kit that is powered by two AA batteries and fits in the palm of a hand. Lucira designed its test kits to provide accurate, reliable and on-the-spot molecular test results anywhere and at any time. The LUCIRA COVID-19 All-In-One Test Kit is designed to provide a clinically relevant COVID-19 result within 30 minutes from sample collection.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210209006142/en/
FAQ
What was the public offering price for Lucira Health's IPO?
How much money did Lucira Health raise from its IPO?
When did Lucira Health's stock begin trading on Nasdaq?
Who managed Lucira Health's IPO?
